Chemomab Therapeutics Ltd reports results for the quarter ended in June - Earnings Summary

Chemomab Therapeutics

12/08/2022 13:00

* Chemomab Therapeutics Ltd  CMMB.OQ  reported a quarterly
adjusted loss of 54 cents​​ per share for the quarter ended in
June. The mean expectation of three analysts for the quarter was
for a loss of 25 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Chemomab Therapeutics Ltd's reported EPS for the quarter
was a
loss of 54 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Chemomab Therapeutics Ltd shares had risen by 0.8% this
quarter and lost 45.9% so far this year.
    * The company reported a quarterly loss of $6.19 million.
    * Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is $21.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 12
at 12:00 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.25          -0.54          Missed
 Mar. 31 2022      -0.24          -0.44          Missed
 Dec. 31 2021      -0.10          -0.44          Missed
 Sep. 30 2021      -0.14          -0.26          Missed